All In Biotech

Drug Trial Radar · NCT03859921

Oral Dydrogesterone as Luteal Phase Support in Natural Cycle FET

A Randomized Double Blind Controlled Comparison of Oral Dydrogesterone as Luteal Phase Support in Natural Cycle Frozen-thawed Embryo Transfer

Last checked: Nov 20, 2026Latest source record: Jun 12, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 716 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

716

Planned (sponsor's estimate)

Start

Jul 1, 2021

Primary completion

Dec 30, 2025

Study completion Nov 30, 2026

Sponsor

Lead sponsor
The University of Hong KongAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Mar 1, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years, up to 42 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This randomised double-blinded controlled trial aims to compare the live birth rate in natural FET cycles with and without oral dydrogesterone as luteal phase support. The hypothesis is that the use of oral dydrogesterone will increase the live birth rate of natural cycle FET.

Conditions

  • Subfertility

Interventions

  • DydrogesteroneDrug

    Progesterone

  • PlaceboDrug

    Placebo with appearance similar to Dydrogesterone

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. live birth rateTime frame: 10 months after recruitment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Department of Obstetrics and Gynaecology

    Hong Kong, Hong Kong, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.